Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease, Seventh Edition (7^th Ed.) Volume 1

SECTION I. GENERAL CONCEPTS AND TOOLS
1. Mendelian, non-mendelian, multigenic inheritance and epigenetics
2. Precision medicine in neurology
3. Epigenomics of Neurological Disorders
4. What Genes can and cannot do
5. Genotype-Phenotype Considerations in Neurogenetic Disease
7. Pharmacogenomic Approaches to the Treatment of Sporadic Alzheimer's Disease
8. Application of Mouse Genetics to Human Disease: Generation and Analysis of Mouse Models
9. DNA sequencing and other methods of exonic and genomic analyses
10. Association, cause and causal association. Revision 2: Playing the changes.
11. Adeno-associated virus-mediated gene therapy in central nervous system genetic disorders
12. Genomics of Human Neurological Disorders
13. CRISPR/Cas9-based Genetic Engineering for Translational Research in Neurological Disorders
14. Neural cells derived from pluripotent stem cells and directly induced from somatic cells
15. Neuroimaging in Dementias
16. Ethics
17. Genetic counseling
18. Antisense oligonucleotide drugs for neurological and neuromuscular disease
19. Autophagy and Neurological Disorders
20. The Aging Brain

SECTION II. NEUROLOGIC DISEASES
21. Cerebral Malformations
22. Global Developmental Delay and Intellectual Disability
23. Aging and Dementia in Down Syndrome
24. An Overview of Rett syndrome
25. Fragile X Clinical Features and Neurobiology
26. Neurological Evaluation and Management of Autism Spectrum Disorder
27. Angelman syndrome
28. Prion diseases
29. Leptin Related Disorders of the Nervous System
30. Genetics of Autonomic Disorders

SECTION III. NEUROMETABOLIC DISORDERS
Sub-Section: Mitochondrial Disorders
31. The Mitochondrial Genome
32. Mitochondrial Disorders Due to Mutations in the Mitochondrial Genome
33. Mitochondrial Disorders Due to Mutations in the Nuclear Genome
34. Pyruvate Dehydrogenase, Pyruvate Carboxylase, Krebs Cycle and Mitochondrial Transport Disorders

Sub-Section: Lysosomal Disorders
35. Gaucher Disease – Neuronopathic Forms
36. The Niemann-Pick Diseases
37. The GM2-Gangliosidoses
38. Metachromatic Leukodystrophy and Multiple Sulfatase Deficiency
39. Krabbe Disease: Globoid Cell Leukodystrophy
40. The Leukodystrophies: An Overview
41. Mucopolysaccharidoses
42. Mucolipidoses
43. Disorders of glycoprotein degradation: a-mannosidosis, ß-mannosidosis, fucosidosis, sialidosis, and aspartylglycosaminuria
44. GM1 Gangliosidosis, Morquio Disease, Galactosialidosis and Sialidosis
45. Acid Ceramidase Deficiency: Farber Lipogranulomatosis, Spinal Muscular Atrophy Associated with Progressive Myoclonic Epilepsy and Peripheral Osteolysis
46. Wolman Disease
47. Lysosomal membrane disorders: lysosome-associated membrane protein-2 deficiency (Danon disease)
48. Fabry Disease: a-Galactosidase A Deficiency
49. Schindler Disease: Deficient-N-Acetylgalactosaminidase Activity

SECTION IV: METABOLIC DISORDERS
50. Organic acid disorders
51. Glycogen and Polyglucosan Storage Diseases
52. Disorders of Galactose Metabolism
53. Inborn Errors of Amino Acid Metabolism
54. Urea Cycle Disorders
55. Glucose transporter type I deficiency and other glucose flux disorders
56. Maple syrup urine disease: biochemical, clinical and therapeutic considerations
57. Congenital Disorders of N-linked Glycosylation
58. Disorders of Glutathione Metabolism
59. Canavan Disease
60. Neurotransmitter disorders
61. Peroxisomal disorders
62. Purines and Pyrimidines
63. The Acute Porphyrias

Roger N. Rosenberg, MD is a graduate of Northwestern University Medical School, With Distinction, and was subsequently trained in Neurology with H. Houston Merritt, MD at the Neurological Institute, Columbia University, New York, was Chief Resident and then was a Post-Doctoral Fellow with Nobel Laureate Marshall Nirenberg at the NIH in the Laboratory of Biochemical Genetics. He is Board Certified by the American Board of Psychiatry and Neurology. He is holder of the Zale Distinguished Chair and Professor of Neurology and Neurotherapeutics at the University of Texas Southwestern Medical Center at Dallas since 1973 and developed the department for 18 years as Chair from 1973-1991.
He described for the first time in 1975 Machado Joseph disease, an autosomal dominant cerebellar degeneration, which produces imbalance and impaired coordination, and showed it was due to a unique expansion of DNA in the causal gene. It is the most common inherited form of impaired coordination in the world and his research has provided a genetic marker to eliminate it in large families in future generations.
He has served as the Founding Director of the UT Southwestern NIH funded Alzheimer’s Disease Center and Principal Investigator of the NIH Center Grant from 1987-2019.
He directs an active laboratory effort in Alzheimer’s Disease. He is developing a DNA Aß42 trimer vaccine for Alzheimer's disease for which he was awarded a US Patent "Amyloid Beta Gene Vaccines" in January 2009. It has been tested in mouse, transgenic mouse, New Zealand white rabbits and rhesus monkeys. The vaccine produces effective anti-Aß42 peptide antibody levels and is non-inflammatory in all three species. The vaccine reduces by 40% Aß42 peptide and by 50% tau and phospho-tau in the brains of 3X AD Tg mice, the two main pathologies of Alzheimer’s disease, with high levels of anti-Aß42 antibody and with a non-inflammatory immune response. He is preparing now a Phase 1 Clinical trial Grant - First in Hu